Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Amyotrophic Lateral Sclerosis Progression: Iran-Als Clinical Registry, a Multicentre Study Publisher Pubmed



Shamshiri H1 ; Fatehi F1 ; Davoudi F2 ; Mir E3 ; Pourmirza B3 ; Abolfazli R1 ; Etemadifar M4 ; Harirchian MH1 ; Gharagozli K5 ; Ayromlou H6 ; Basiri K4 ; Zamani B7 ; Rohani M7 ; Sedighi B8 Show All Authors
Authors
  1. Shamshiri H1
  2. Fatehi F1
  3. Davoudi F2
  4. Mir E3
  5. Pourmirza B3
  6. Abolfazli R1
  7. Etemadifar M4
  8. Harirchian MH1
  9. Gharagozli K5
  10. Ayromlou H6
  11. Basiri K4
  12. Zamani B7
  13. Rohani M7
  14. Sedighi B8
  15. Roudbari A9
  16. Delavar Kasmaei H5
  17. Nikkhah K10
  18. Ranjbar Naeini A11
  19. Nafissi S1

Source: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Published:2015


Abstract

This study was designed to evaluate ALS progression among different subgroups of Iranian patients.Three hundred and fifty-eight patients from centres around the country were registered and their progression rate was evaluated using several scores including Manual Muscle Test scoring (MMT) and the revised ALS Functional Rating Scale (ALSFRS-R). Progression rate was analysed separately in subgroups regarding gender, onset site, stage of disease and riluzole consumption. A significant difference in MMT deterioration rate (p = 0.01) was noted between those who used riluzole and those who did not. No significant difference was observed in progression rates between male/female and bulbar-onset/limb-onset groups using riluzole. In conclusion, riluzole has a significant effect on muscle force deterioration rate but not functional scale. Progression rate was not influenced by site of onset or gender. © 2015 Taylor & Francis.